Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Asenapine, sold under the brand name Saphris among others, is an atypical antipsychotic medication used to treat schizophrenia and acute mania associated with bipolar disorder as well as the medium to long-term management of bipolar disorder.
Applications & Standards
Explore the main themes, entities and connections around Asenapine. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
atypical acute schizophrenia disorder bipolar antipsychotic mania symptoms name significantly olanzapine receptors include found meta-analysis approved medication effects drug transdermal
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Asenapine | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Asenapine | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Asenapine | ATC code | N05AH05 (WHO) | 1.00 | infobox |
| Asenapine | Bioavailability | 35% (sublingual), <2% (oral), transdermal bioavailability is significantly higher than sublingual | 1.00 | infobox |
| Asenapine | CAS Number | 65576-45-6 N | 1.00 | infobox |
| Asenapine | CAS Number | as salt: 85650-56-2 | 1.00 | infobox |
| Asenapine | ChEBI | CHEBI:71253 N | 1.00 | infobox |
| Asenapine | ChEBI | as salt: CHEBI:71245 | 1.00 | infobox |
| Asenapine | ChEMBL | ChEMBL1201756 N | 1.00 | infobox |
| Asenapine | ChEMBL | as salt: ChEMBL2040684 | 1.00 | infobox |
| Asenapine | ChemSpider | 2300725 Y | 1.00 | infobox |
| Asenapine | ChemSpider | as salt: 5293095 | 1.00 | infobox |
| Asenapine | Drug class | Atypical antipsychotic | 1.00 | infobox |
| Asenapine | DrugBank | DB06216 | 1.00 | infobox |
| Asenapine | DrugBank | as salt: DBSALT000010 | 1.00 | infobox |
| Asenapine | ECHA InfoCard | 100.059.828 | 1.00 | infobox |
| Asenapine | Elimination half-life | 24 hours (sublingual), 30 hours (transdermal), 33.9 hours (transdermal) | 1.00 | infobox |
| Asenapine | Excretion | Kidney (50%), Fecal (40%; ~5–16% as unchanged drug in feces) | 1.00 | infobox |
| Asenapine | Formula | C17H16ClNO | 1.00 | infobox |
| Asenapine | IUPHAR/BPS | 22 | 1.00 | infobox |
| Asenapine | KEGG | D11769 | 1.00 | infobox |
| Asenapine | KEGG | as salt: D02995 | 1.00 | infobox |
| Asenapine | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Asenapine | Legal status | BR: Class C1 (Other controlled substances) | 1.00 | infobox |
| Asenapine | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Asenapine | Legal status | US: ℞-only | 1.00 | infobox |
| Asenapine | Legal status | EU: Rx-only | 1.00 | infobox |
| Asenapine | License data | EU EMA: by INN | 1.00 | infobox |
| Asenapine | License data | US DailyMed: Asenapine | 1.00 | infobox |
| Asenapine | License data | US FDA: Asenapine | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.